查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1595126

卵巢癌诊断市场：按癌症类型、诊断类型和最终用户划分 - 全球预测 2025-2030

Ovarian Cancer Diagnostics Market by Cancer Type (Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor), Diagnosis Type (Biopsy, Blood Test, Imaging), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年卵巢癌诊断市场价值为71.7亿美元，预计到2024年将达到81.8亿美元，复合年增长率为14.50%，到2030年将达到185亿美元。

卵巢癌诊断市场的范围和定义包括用于卵巢癌早期检测、诊断和监测的各种测试和技术。由于卵巢癌通常在晚期才被发现，因此改进诊断方法对于提高患者存活率至关重要。这些诊断的应用扩展到医院、实验室和诊所，最终用户包括医疗保健相关人员、研究人员和易患卵巢癌的个人。影响市场成长的主要因素包括卵巢癌盛行率的上升、液态切片和诊断成像技术等诊断技术的进步以及对癌症早期检测的认识不断提高。此外，政府对癌症研究的措施和资助也有助于市场扩张。开发非侵入性诊断工具、增强生物标记识别以及整合人工智慧以提高诊断准确性存在机会。这些可能会鼓励製药公司和研究机构的技术创新。

主要市场统计
基准年[2023] 71.7亿美元
预测年份 [2024] 81.8亿美元
预测年份 [2030] 185亿美元
复合年增长率（%） 14.50%

然而，准确诊断面临重大挑战，包括诊断成本高、低收入地区的可用性有限以及卵巢癌病理学的复杂性。此外，严格的监管政策可能会推迟新诊断工具的核准。为了克服这些挑战，公司应该专注于具有成本效益和扩充性的诊断解决方案，特别是对于服务不足的市场。最佳创新领域是开发结合成像、生物标记和基因检测的多模态诊断方法。此外，用于连续监测的可穿戴技术的发展有可能彻底改变早期诊断工作。总体而言，该市场是一个充满活力的市场，具有高成长潜力，受到技术进步和对精确诊断不断增长的需求的推动，但受到成本、可及性和监管障碍的限制。寻求发展的公司应优先考虑研发方面的合作和伙伴关係，并专注于开发人工智慧主导的诊断技术，以提高市场渗透率和患者治疗效果。

市场动态：快速发展的卵巢癌诊断市场的关键市场洞察

供需的动态交互作用正在改变卵巢癌诊断市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 增加政府对卵巢癌研究的承诺和资助
    • 全球女性卵巢癌盛行率不断上升
    • 早期诊断和治疗的潜在需求
  • 市场限制因素
    • 诊断费用相对较高，人们担心治疗的副作用。
  • 市场机会
    • 现代化的兴起和卵巢癌诊断工具的进步
    • 继续应用联合治疗治疗卵巢癌
  • 市场挑战
    • 对卵巢癌的认识降低且缺乏准确诊断

波特五力：开拓卵巢癌诊断市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解卵巢癌诊断市场的外部影响

外部宏观环境因素在塑造卵巢癌诊断市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解卵巢癌诊断药物市场的竞争状况

卵巢癌诊断市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵卵巢癌诊断市场供应商绩效评估

FPNV定位矩阵是评估卵巢癌诊断市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了卵巢癌诊断市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，对卵巢癌诊断市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告提供了涵盖关键重点领域的市场全面分析：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 政府对卵巢癌研究的积极承诺和增加资金
      • 全球女性卵巢癌发生率呈上升趋势
      • 早期诊断和治疗的潜在需求
    • 抑制因素
      • 诊断费用相对较高，且患者担心治疗副作用。
    • 机会
      • 卵巢癌诊断技术的现代化与进步
      • 联合治疗在卵巢癌治疗的持续应用
    • 任务
      • 对卵巢癌的认识下降和缺乏准确诊断
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章按癌症类型分類的卵巢癌诊断药物市场

  • 上皮性肿瘤
  • 生殖细胞肿瘤
  • 间质细胞瘤

第七章依诊断类型分類的卵巢癌诊断药物市场

  • 切片检查
  • 验血
    • BRCA
    • CA125
    • 印度核能管理局
    • 急诊室及公关
    • HER2
    • KRAS突变
  • 影像
    • 电脑断层扫描
    • 核磁共振扫描
    • 正子断层扫描
    • 超音波

第八章卵巢癌诊断市场：依最终用户分类

  • 癌症诊断中心
  • 医院实验室
  • 调查机构

第九章北美和南美卵巢癌诊断药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区卵巢癌诊断市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲的卵巢癌诊断市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories Ltd.
  • Almac Group
  • Apollo Diagnostics
  • AstraZeneca PLC
  • Avalon Health Economics LLC
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Laboratory Corporation of America Holdings
  • MedGenome Labs Ltd.
  • Myriad Genetics Inc.
  • Oncgnostics GmbH
  • Ovation Diagnostics LLC
  • Pfizer, Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-ED54C46E9279

The Ovarian Cancer Diagnostics Market was valued at USD 7.17 billion in 2023, expected to reach USD 8.18 billion in 2024, and is projected to grow at a CAGR of 14.50%, to USD 18.50 billion by 2030.

The scope and definition of the ovarian cancer diagnostics market encompass a range of tests and technologies employed for the early detection, diagnosis, and monitoring of ovarian cancer. As ovarian cancer is often detected in advanced stages, the necessity for improved diagnostics is critical to enhance patient survival rates. The application of these diagnostics extends to hospitals, research labs, and clinics, while end-users include medical professionals, researchers, and individuals with a predisposition to ovarian cancer. Key factors influencing market growth include the rising prevalence of ovarian cancer, advancements in diagnostic technologies like liquid biopsies and imaging techniques, and increased awareness about early cancer detection. Additionally, government initiatives and funding aimed at cancer research contribute to market expansion. Opportunities lie in the development of non-invasive diagnostic tools, enhanced biomarker identification, and the integration of artificial intelligence to improve diagnostic accuracy. These will encourage pharmaceutical companies and research institutions to innovate.

KEY MARKET STATISTICS
Base Year [2023] USD 7.17 billion
Estimated Year [2024] USD 8.18 billion
Forecast Year [2030] USD 18.50 billion
CAGR (%) 14.50%

However, there are significant challenges such as high costs of diagnostic procedures, limited availability in low-income regions, and the complexity of ovarian cancer pathology which can impede accurate diagnosis. Moreover, stringent regulatory policies can slow down the approval of novel diagnostic tools. To overcome these challenges, companies should focus on cost-effective and scalable diagnostic solutions, particularly for underserved markets. The best areas of innovation include the development of multi-modal diagnostic approaches that combine imaging, biomarkers, and genetic testing. Furthermore, developing wearable technology for continuous monitoring could revolutionize early diagnosis efforts. Overall, the market is dynamic with high growth potential, driven by technological advancements and increasing demand for precise diagnostics, yet it is limited by cost, accessibility, and regulatory hurdles. Companies aiming for growth should prioritize collaborations and partnerships for research and development, and focus on developing AI-driven diagnostics to enhance market penetration and patient outcomes.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Ovarian Cancer Diagnostics Market

The Ovarian Cancer Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing favorable government initiatives and growing funding for ovarian cancer research
    • Growing prevalence of ovarian cancer among women worldwide
    • Potential demand for early diagnosis and treatment
  • Market Restraints
    • Relatively high cost of diagnosis and concerns of adverse effects of the treatment among patients
  • Market Opportunities
    • Emerging modernization and advancements in technical diagnostic tools for ovarian cancer
    • Ongoing application of combination therapies to treat ovarian cancer
  • Market Challenges
    • Reduced awareness and dearth of precise diagnosis of ovarian cancer

Porter's Five Forces: A Strategic Tool for Navigating the Ovarian Cancer Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Ovarian Cancer Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Ovarian Cancer Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Ovarian Cancer Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Ovarian Cancer Diagnostics Market

A detailed market share analysis in the Ovarian Cancer Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Ovarian Cancer Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Ovarian Cancer Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Ovarian Cancer Diagnostics Market

A strategic analysis of the Ovarian Cancer Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Ovarian Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories Ltd., Almac Group, Apollo Diagnostics, AstraZeneca PLC, Avalon Health Economics LLC, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Laboratory Corporation of America Holdings, MedGenome Labs Ltd., Myriad Genetics Inc., Oncgnostics GmbH, Ovation Diagnostics LLC, Pfizer, Inc., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Ovarian Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Cancer Type, market is studied across Epithelial Tumor, Germ Cell Tumor, and Stromal Cell Tumor.
  • Based on Diagnosis Type, market is studied across Biopsy, Blood Test, and Imaging. The Blood Test is further studied across BRCA, CA125, CEA, ER & PR, HER2, and KRAS Mutation. The Imaging is further studied across CT Scan, MRI Scan, PET Scan, and Ultrasound.
  • Based on End-User, market is studied across Cancer Diagnostic Centers, Hospital Laboratories, and Research Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing favorable government initiatives and growing funding for ovarian cancer research
      • 5.1.1.2. Growing prevalence of ovarian cancer among women worldwide
      • 5.1.1.3. Potential demand for early diagnosis and treatment
    • 5.1.2. Restraints
      • 5.1.2.1. Relatively high cost of diagnosis and concerns of adverse effects of the treatment among patients
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging modernization and advancements in technical diagnostic tools for ovarian cancer
      • 5.1.3.2. Ongoing application of combination therapies to treat ovarian cancer
    • 5.1.4. Challenges
      • 5.1.4.1. Reduced awareness and dearth of precise diagnosis of ovarian cancer
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Ovarian Cancer Diagnostics Market, by Cancer Type

  • 6.1. Introduction
  • 6.2. Epithelial Tumor
  • 6.3. Germ Cell Tumor
  • 6.4. Stromal Cell Tumor

7. Ovarian Cancer Diagnostics Market, by Diagnosis Type

  • 7.1. Introduction
  • 7.2. Biopsy
  • 7.3. Blood Test
    • 7.3.1. BRCA
    • 7.3.2. CA125
    • 7.3.3. CEA
    • 7.3.4. ER & PR
    • 7.3.5. HER2
    • 7.3.6. KRAS Mutation
  • 7.4. Imaging
    • 7.4.1. CT Scan
    • 7.4.2. MRI Scan
    • 7.4.3. PET Scan
    • 7.4.4. Ultrasound

8. Ovarian Cancer Diagnostics Market, by End-User

  • 8.1. Introduction
  • 8.2. Cancer Diagnostic Centers
  • 8.3. Hospital Laboratories
  • 8.4. Research Institutes

9. Americas Ovarian Cancer Diagnostics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Ovarian Cancer Diagnostics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Ovarian Cancer Diagnostics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories Ltd.
  • 2. Almac Group
  • 3. Apollo Diagnostics
  • 4. AstraZeneca PLC
  • 5. Avalon Health Economics LLC
  • 6. Becton, Dickinson and Company
  • 7. Bio-Rad Laboratories, Inc.
  • 8. F. Hoffmann-La Roche AG
  • 9. GlaxoSmithKline PLC
  • 10. Laboratory Corporation of America Holdings
  • 11. MedGenome Labs Ltd.
  • 12. Myriad Genetics Inc.
  • 13. Oncgnostics GmbH
  • 14. Ovation Diagnostics LLC
  • 15. Pfizer, Inc.
  • 16. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. OVARIAN CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. OVARIAN CANCER DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. OVARIAN CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. OVARIAN CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. OVARIAN CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. OVARIAN CANCER DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY EPITHELIAL TUMOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY GERM CELL TUMOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY STROMAL CELL TUMOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BRCA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CA125, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CEA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY ER & PR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY HER2, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY KRAS MUTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY MRI SCAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY PET SCAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 240. OVARIAN CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 241. OVARIAN CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023